Joel Beatty
Stock Analyst at Baird
(4.18)
# 387
Out of 4,784 analysts
191
Total ratings
41.18%
Success rate
17.36%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LRMR Larimar Therapeutics | Maintains: Outperform | $13 → $10 | $2.35 | +325.53% | 2 | Mar 25, 2025 | |
| MNMD Mind Medicine (MindMed) | Maintains: Outperform | $27 → $16 | $6.19 | +158.48% | 2 | Mar 7, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Outperform | $32 → $16 | $7.07 | +126.31% | 2 | Mar 7, 2025 | |
| ARGX argenx SE | Maintains: Neutral | $650 → $680 | $589.15 | +15.42% | 6 | Mar 4, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $117 → $73 | $38.66 | +88.83% | 2 | Mar 3, 2025 | |
| CPRX Catalyst Pharmaceuticals | Maintains: Outperform | $28 → $32 | $24.69 | +29.61% | 2 | Mar 3, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $132 → $160 | $118.53 | +34.99% | 4 | Mar 3, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $10 → $8 | $6.48 | +23.46% | 4 | Feb 27, 2025 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $31 | $14.78 | +109.74% | 1 | Jan 7, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $10 → $8 | $1.25 | +540.00% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $70 | $54.24 | +29.06% | 14 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $36.50 | +105.48% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $154 → $162 | $122.92 | +31.79% | 3 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $11 | $3.66 | +200.55% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $1.86 | +276.34% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $72 | $14.52 | +395.87% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $71.44 | -9.01% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $240 → $175 | $64.83 | +169.94% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $9 | $8.28 | +8.70% | 4 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $112 → $127 | $88.72 | +43.15% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $58 | $19.99 | +190.15% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $38 | $33.21 | +14.42% | 2 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $37.82 | +90.38% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $20 | $0.65 | +2,976.92% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $17.07 | +64.03% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.65 | +172.73% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $103 | $131.81 | -21.86% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $12.15 | +105.76% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $0.32 | +2,742.70% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $13.18 | +112.44% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $7.52 | +112.77% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $8.50 | -17.65% | 1 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.44 | -13.19% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.47 | +2,893.20% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $13.82 | +319.68% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $17.05 | +40.76% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $11.58 | +55.44% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $3.29 | +82.37% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $46 → $31 | $1.24 | +2,400.00% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $6.70 | +317.91% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $268.46 | -34.81% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $4.69 | +198.51% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $70.41 | +53.39% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $31.15 | +150.40% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $6.20 | +1,512.90% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $6 | $0.44 | +1,263.02% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $0.25 | +5,900.00% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.50 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $7.00 | +114.29% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $0.71 | +16,801.41% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $7.05 | +169.50% | 3 | Nov 10, 2017 |
Larimar Therapeutics
Mar 25, 2025
Maintains: Outperform
Price Target: $13 → $10
Current: $2.35
Upside: +325.53%
Mind Medicine (MindMed)
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $6.19
Upside: +158.48%
Contineum Therapeutics
Mar 7, 2025
Maintains: Outperform
Price Target: $32 → $16
Current: $7.07
Upside: +126.31%
argenx SE
Mar 4, 2025
Maintains: Neutral
Price Target: $650 → $680
Current: $589.15
Upside: +15.42%
Praxis Precision Medicines
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $38.66
Upside: +88.83%
Catalyst Pharmaceuticals
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $24.69
Upside: +29.61%
Axsome Therapeutics
Mar 3, 2025
Maintains: Outperform
Price Target: $132 → $160
Current: $118.53
Upside: +34.99%
Cogent Biosciences
Feb 27, 2025
Maintains: Neutral
Price Target: $10 → $8
Current: $6.48
Upside: +23.46%
Denali Therapeutics
Jan 7, 2025
Initiates: Outperform
Price Target: $31
Current: $14.78
Upside: +109.74%
Editas Medicine
Dec 13, 2024
Maintains: Outperform
Price Target: $10 → $8
Current: $1.25
Upside: +540.00%
Dec 3, 2024
Maintains: Outperform
Price Target: $52 → $70
Current: $54.24
Upside: +29.06%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $36.50
Upside: +105.48%
Nov 18, 2024
Maintains: Outperform
Price Target: $154 → $162
Current: $122.92
Upside: +31.79%
Nov 18, 2024
Upgrades: Outperform
Price Target: $3 → $11
Current: $3.66
Upside: +200.55%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.86
Upside: +276.34%
Nov 12, 2024
Maintains: Outperform
Price Target: $54 → $72
Current: $14.52
Upside: +395.87%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $71.44
Upside: -9.01%
Oct 21, 2024
Maintains: Outperform
Price Target: $240 → $175
Current: $64.83
Upside: +169.94%
Oct 9, 2024
Maintains: Neutral
Price Target: $13 → $9
Current: $8.28
Upside: +8.70%
Aug 2, 2024
Maintains: Outperform
Price Target: $112 → $127
Current: $88.72
Upside: +43.15%
Jul 26, 2024
Initiates: Outperform
Price Target: $58
Current: $19.99
Upside: +190.15%
Jul 25, 2024
Maintains: Outperform
Price Target: $37 → $38
Current: $33.21
Upside: +14.42%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $37.82
Upside: +90.38%
May 15, 2024
Maintains: Outperform
Price Target: $45 → $20
Current: $0.65
Upside: +2,976.92%
May 9, 2024
Maintains: Outperform
Price Target: $31 → $28
Current: $17.07
Upside: +64.03%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.65
Upside: +172.73%
Apr 17, 2024
Maintains: Outperform
Price Target: $83 → $103
Current: $131.81
Upside: -21.86%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $12.15
Upside: +105.76%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $0.32
Upside: +2,742.70%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $13.18
Upside: +112.44%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $7.52
Upside: +112.77%
May 23, 2023
Initiates: Outperform
Price Target: $7
Current: $8.50
Upside: -17.65%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.44
Upside: -13.19%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.47
Upside: +2,893.20%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $13.82
Upside: +319.68%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $17.05
Upside: +40.76%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $11.58
Upside: +55.44%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $3.29
Upside: +82.37%
Jun 1, 2022
Maintains: Outperform
Price Target: $46 → $31
Current: $1.24
Upside: +2,400.00%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $6.70
Upside: +317.91%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $268.46
Upside: -34.81%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $4.69
Upside: +198.51%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $70.41
Upside: +53.39%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $31.15
Upside: +150.40%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $6.20
Upside: +1,512.90%
Apr 1, 2020
Maintains: Buy
Price Target: $24 → $6
Current: $0.44
Upside: +1,263.02%
Mar 26, 2020
Maintains: Buy
Price Target: $16 → $15
Current: $0.25
Upside: +5,900.00%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $1.50
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $7.00
Upside: +114.29%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $0.71
Upside: +16,801.41%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $7.05
Upside: +169.50%